Drug intelligence / Profile preview

OVV-05

Development stage: Preclinical
Lead developer: Li Ning
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intratumoral, Intravenous, Intraperitoneal

Overview

OVV-05 is a preclinical-stage oncolytic virus therapy being developed by Joint Biosciences for the treatment of solid tumors. The agent is based on a Vesicular Stomatitis Virus (VSV) platform engineered to target mesothelin (MSLN), a cell surface glycoprotein that is highly expressed in several malignancies, including mesothelioma, pancreatic, and ovarian cancers. OVV-05 is designed to selectively infect and replicate within MSLN-expressing tumor cells, leading to direct tumor cell lysis. This process not only destroys the primary tumor cells but also potentially releases tumor-associated antigens that can stimulate a systemic anti-tumor immune response.

Other names: VSV-MLSN

Targets

Mesothelin

Beyond the preview

Go deeper on OVV-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OVV-05.

Explore the full profile